Table 1.

Clinical and laboratory characteristics of 75 control subjects and 75 Type 2 diabetic patients.

	Control Subjects (n = 75)	Type 2 Diabetic Subjects (n = 75)	p-Value
Age (year)	55 ± 10	59 ± 9	0.014
Sex (M/F)	36/39	47/28	0.10
BMI (kg/m2)	25.9 ± 3.9	28.7 ± 4.9	<0.001
Systolic blood pressure (mmHg)	131 ± 20	144 ± 20	<0.001
Diastolic blood pressure (mmHg)	82 ± 11	87 ± 9	<0.001
Plasma glucose (mmol/L)	5.6 ± 0.7	8.8 ± 2.4	<0.001
HbA1c (%)	5.3 ± 0.4	6.7 ± 1.0	<0.001
Total cholesterol (mmol/L)	5.67 ± 0.98	5.40 ± 0.98	0.07
Non-HDL cholesterol (mmol/L)	4.20 ± 1.00	4.12 ± 1.07	0.65
HDL cholesterol (mmol/L)	1.49 ± 0.40	1.28 ± 0.38	0.001
Triglycerides (mmol/L)	1.31 (0.87–1.91)	1.73 (1.17–2.17)	0.036
Apolipoprotein A-1 (g/L)	1.42 ± 0.22	1.28 ± 0.38	0.030
Apolipoprotein B (g/L)	0.95 ± 0.23	0.93 ± 0.23	0.77
CEC (% per 4 h)	8.56 ± 1.00	8.66 ± 0.90	0.52
Pre-β-HDL formation (apoA-1, g/L)	0.31 ± 0.07	0.30 ± 0.07	0.31
PLTP activity (AU)	94.0 ± 10.5	103.6 ± 11.4	<0.001
LCAT activity (AU)	106.8 ± 13.1	114.1 ± 17.4	0.004
EST (nmol/mL/h)	56.1 ± 15.6	63.6 ± 18.9	0.009
CETP mass (mg/L)	2.16 ± 0.67	2.49 ± 0.90	0.011
CET (nmol/mL/h)	20.6 ± 7.5	24.1 ± 9.0	0.011
AAA1(AU)	0.35 (0.24–0.45)	0.27 (0.18–0.39)	0.16
AAc-terAA1 (AU)	0.23 (0.19–0.36)	0.22 (0.15–0.29)	0.17

Data in numbers, mean ± SD or median (interquartile range). AAA1 and Ac-terAA1 autoantibodies are expressed as arbitrary units (AU). BMI, body mass index; CEC, cholesterol efflux capacity; CET, cholesteryl ester transfer; CETP, cholesteryl ester transfer protein; EST, cholesterol esterification; HDL, high-density lipoprotein; LCAT, lecithin–cholesterol acylesterase; PLTP, phospholipid transfer protein. Comparisons are done by unpaired t-tests or Chi square analysis. Triglycerides and AUs for AAA1 and Ac-terAA1 autoantibodies are log_e transformed.